Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
OTC Markets EXMKT - Delayed Quote USD

Nicox S.A. (NICXF)

Compare
0.2400
0.0000
(0.00%)
At close: February 26 at 3:00:00 PM EST
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
257
257
212
8,583
14,423
Cost of Revenue
11,760
11,760
-23,345
1,350
1,516
Gross Profit
-11,503
-11,503
23,557
7,233
12,907
Operating Expense
6,000
6,000
16,513
25,399
19,920
Operating Income
-17,503
-17,503
7,044
-18,166
-7,013
Net Non Operating Interest Income Expense
-734
-734
-859
-4,798
-8,084
Pretax Income
-21,422
-21,422
-31,789
-47,405
-18,070
Tax Provision
-478
-478
-504
-3,644
28
Net Income Common Stockholders
-20,881
-20,881
-31,285
-43,761
-18,098
Diluted NI Available to Com Stockholders
-20,881
-20,881
-31,285
-43,761
-18,098
Basic EPS
-0.37
-0.42
-0.62
-1.17
-0.54
Diluted EPS
-0.37
-0.42
-0.62
-1.17
-0.54
Basic Average Shares
47,443.8540
50,170.4980
50,100.4480
37,486.5700
33,717.6260
Diluted Average Shares
50,170.4980
50,170.4980
50,100.4480
37,486.5700
33,717.6260
Total Operating Income as Reported
--
--
-34,061
-46,010
-6,760
Total Expenses
17,760
17,760
-6,832
26,749
21,436
Net Income from Continuing & Discontinued Operation
-20,944
-20,944
-31,285
-43,761
-18,098
Normalized Income
-20,944
-20,944
-31,285
-18,135.7440
-18,098
Interest Income
1,099
1,099
1,120
--
891
Interest Expense
1,633
1,633
1,630
2,023
2,205
Net Interest Income
-734
-734
-859
-4,798
-8,084
EBIT
-19,789
-19,789
-30,159
-45,382
-15,865
EBITDA
-16,238
-16,238
-18,101
-15,961
-14,122
Reconciled Cost of Revenue
11,760
11,760
-23,345
1,350
1,516
Reconciled Depreciation
3,551
3,551
11,216
29,421
1,743
Net Income from Continuing Operation Net Minority Interest
-20,944
-20,944
-31,285
-43,761
-18,098
Total Unusual Items Excluding Goodwill
--
--
-12,329
-27,760
--
Total Unusual Items
--
--
-12,329
-27,760
--
Normalized EBITDA
-16,238
-16,238
-18,101
11,799
-14,122
Tax Rate for Calcs
0
0
0
0.0001
0.0003
Tax Effect of Unusual Items
--
--
--
-2,134.7440
--
12/31/2020 - 2/22/2010

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

430.BE Terns Pharmaceuticals Inc
3.6000
+1.12%
 
ANL Adlai Nortye Ltd.
2.2203
+0.92%
 
TRDA Entrada Therapeutics, Inc.
12.02
-0.83%
 
CGEM Cullinan Therapeutics, Inc.
8.45
-1.29%
 
IMCR Immunocore Holdings plc
30.77
+5.34%
 
MNPR Monopar Therapeutics Inc.
31.29
+0.58%
 
AGIO Agios Pharmaceuticals, Inc.
34.44
-2.13%
 
BRTX BioRestorative Therapies, Inc.
1.9100
+4.95%
 
HEPA Hepion Pharmaceuticals, Inc.
0.1560
+1.83%
 
PTGX Protagonist Therapeutics, Inc.
36.15
+3.02%